Daily variation in circulating cytokines and acute-phase proteins correlates with clinical and laboratory indices in community-acquired pneumonia

European Journal of Clinical Investigation

Volumn 27, Issue 4, 1997, Pages 308-315

  Kosmas, E N ^a   Baxevanis, C N ^b   Papamichail, M ^b   Kordossis, T ^c  

^a 'A Fleming' General Hospital   (Greece)

^b Hellenic Anticancer Institute   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Acute phase proteins; Community acquired pneumonia; Fibronectin; Proinflammatory cytokine

Indexed keywords

ACUTE PHASE PROTEIN; C REACTIVE PROTEIN; CYTOKINE; FIBRONECTIN; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ACUTE PHASE RESPONSE; ADULT; ARTICLE; CLINICAL ARTICLE; ERYTHROCYTE SEDIMENTATION RATE; FEVER; HUMAN; NEUTROPHIL; PNEUMONIA; PRIORITY JOURNAL;

EID: 0030980585     PISSN: 00142972     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2362.1997.1030656.x     Document Type: Article

References (35)

1. Kushner I. The phenomenon of the acute phase response. Ann NY Acad Sci 1982;389:39-48.
2. Baumann H, Prowse KR, Marinkovic S, Won A, Jahreis GP. Stimulation of hepatic acute phase response by cytokines and glucocorticoids. Ann NY Acad Sci 1989;557:280-95.
3. Woo P. The acute phase response. In: Panayi GS, ed. Immunology of Connective Tissue Diseases. New York: Kluwer Academic Publishers, 1994;147-56.
4. Bohte R, van Furth R, van den Broek PJ. Aetiology of community-acquired pneumonia: a prospective study among adults requiring admission to hospital. Thorax 1995;50:543-7.
5. Marrie TJ. Community-acquired pneumonia. Clin Infect Dis 1994;18:501-15.
6. Laurell CB. Electroimmunoassay. Scand J Clin Lab Invest 1972;29:21-5.
7. Eriksen HD, Clemmensen I, Hansen MS, Ibsen KK. Plasma fibronectin concentration in normal subjects. Scand J Clin Lab Invest 1982;42:291-6.
8. Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics 1982;38:963-74.
9. Mittl RL Jr, Schwab RJ, Duchin JS, Coin JE, Albeida SM, Miller WT. Radiographic resolution of community-acquired pneumonia. Am J Respir Crit Care Med 1994;149:630-5.
10. Rello J. Community-acquired pneumonia. Curr Opin Pulm Med 1995;1:183-7.
11. Niederman MS, Bass JB, Campbell GD et al. Guidelines for the initial management of adults with community-acquired pneumonia: diagnosis, assessment of severity and initial antimicrobial therapy. Am Rev Respir Dis 1993;148:1418-26.
12. Mason CM, Kolls JK, Nelson S. Pathogenesis and host defense in pulmonary infections. Curr Opin Pulm Med 1995;1:163-70.
13. Tuomanen EI, Austrian R, Masure HR. Pathogenesis of pneumococcal infection. N Engl J Med 1995;332:1280-4.
14. Wilson AG, Duff GW. Cytokines and inflammatory arthritis. In: Panayi GS, ed. Immunology of Connective Tissue Diseases. New York: Kluwer Academic Publishers, 1994;83-93.
15. Remick DG. Cytokines and septic shock. In: Griffin GE, ed. Cytokines in Infection. London: Bailliere Tindall, 1994;37-50.
16. Fisher CJ Jr, Opal SM, Dhainaut JF et al. Influence of an anti-tumor necrosis factor monoclonal antibody on cytokine levels in patients with sepsis. Crit Care Med 1993;21:318-27.
17. Larrick JW, Graham D, Toy K et al. Recombinant tumor necrosis factor causes activation of human granulocytes. Blood 1987;69:640-4.
18. Damas P, Reuter A, Gysen P et al. Tumor necrosis factor and interleukin-1 serum levels during severe sepsis in humans. Crit Care Med 1989;17:975-8.
19. Cannon JG, Tompkins RG, Gelfand JA et al. Circulating interleukin-1 and tumor necrosis factor in septic shock and experimental endotoxin fever. J Infect Dis 1990;161:79-94.
20. Damas P, Ledoux D, Nys M et al. Cytokine serum level during severe sepsis in human IL-6 as a marker of severity. Ann Surg 1992;215:356-62.
21. Dofferhoff AS, Bom VJ, de Vries-Hospers et al. Patterns of cytokines, plasma endotoxin, plasminogen activator inhibitor and acute phase proteins during the treatment of severe sepsis in humans. Crit Care Med 1992;20:185-92.
22. Endo S, Inada K, Inoue Y et al. Two types of septic shock classified by the plasma levels of cytokines and endotoxin. Circ Shock 1992;38:264-74.
23. Waage A, Halstensen A, Espevik T. Association between tumour necrosis factor in serum and fatal outcome in patients with meningococcal disease. Lancet 1987;1:355-7.
24. Debets JM, Kampmeijer R, van der Linden MP et al. Plasma tumor necrosis factor and mortality in critically ill septic patients. Crit Care Med 1989;17:489-94.
25. Offner E, Philippe J, Vogelaers D et al. Serum tumor necrosis factor levels in patients with infectious disease and septic shock. J Lab Clin Med 1990;116:100-5.
26. Marks JD, Marks CB, Luce JM et al. Plasma tumor necrosis factor in patients with septic shock. Mortality rate, incidence of adult respiratory distress syndrome, and effects of methylprednizolone administration. Am Rev Respir Dis 1990;141:94-7.
27. Calandra T, Baumgartner JD, Grau GE et al. Prognostic values of tumor necrosis factor/cachectin, interleukin-1, interferon-alpha and interferon-gamma in the serum of patients with septic shock. J Infect Dis 1990;161:982-7.
28. van Deuren M, van der ven-Jongekrijg J, Bartelink AKM, van Dalen R, Sauerwein RW, van der Meer JWM. Correlation between proinflammatory cytokines and antiinflammatory mediators and the severity of disease in meningococcal infections. J Infect Dis 1995;172:433-9.
29. Kindler V, Sappino A, Grau G, Piguet P, Vassalli P. The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection. Cell 1989;56:731-40.
30. Denis M. Involvement of cytokines in determining resistance and acquired immunity in murine tuberculosis. J Leukoc Biol 1991;50:495-501.
31. Denis M, Ghadirian E. Interleukin-1 is involved in mouse resistance to Mycobacterium avium. Infect Immun 1994;62:457-61.
32. Fisher CJ Jr, Slotman GJ, Opal SM et al. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial. Crit Care Med 1994;22:12-21.
33. Fisher CJ Jr, Dhainaut JF, Opal SM et al. Recombinant human interleukin-1 receptor antagonist in the treatment of patients with sepsis syndrome: results from a randomized, double-blind, placebo-controlled trial. JAMA 1994;271:1836-43.
34. Waage A, Brandtzaeg P, Halstensen A et al. The complex pattern of cytokines in serum from patients with meningococcal septic shock. Association between interleukin-1, interleukin-6 and fatal outcome. J Exp Med 1989;169:333-8.
35. Takaishi M, Sadamoto K, Takami S, Ishioka S, Hozawa S, Yamakido M. Changes in various serum protein levels between acute and convalescent phases in patients with respiratory infections. Jpn J Thorac Dis 1990;28:315-9.